Roman Shimanovich
Schrodinger (United States)(US)Siberian Federal University(RU)
Publications by Year
Research Areas
Liver physiology and pathology, Nitric Oxide and Endothelin Effects, PI3K/AKT/mTOR signaling in cancer, Cancer Mechanisms and Therapy, Psoriasis: Treatment and Pathogenesis
Most-Cited Works
- → Part I: Pathogenetic Role of Peroxynitrite in the Development of Diabetes and Diabetic Vascular Complications: Studies With FP15, A Novel Potent Peroxynitrite Decomposition Catalyst(2002)174 cited
- → Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase(2008)139 cited
- → Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)(2008)94 cited
- → Myoglobin Catalyzes Its Own Nitration(2001)92 cited
- → Mechanisms of Peroxynitrite Decomposition Catalyzed by FeTMPS, a Bioactive Sulfonated Iron Porphyrin(2001)91 cited
- → Mn(II)−Texaphyrin as a Catalyst for the Decomposition of Peroxynitrite(2001)67 cited
- → Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity(2017)67 cited
- → Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors(2009)56 cited
- → In Silico Prediction of Pharmaceutical Degradation Pathways: A Benchmarking Study(2014)52 cited
- → Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity(2016)34 cited